131 related articles for article (PubMed ID: 7601570)
1. Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells.
Masumoto N; Nakano S; Esaki T; Fujishima H; Tatsumoto T; Niho Y
Int J Cancer; 1995 Jul; 62(1):70-5. PubMed ID: 7601570
[TBL] [Abstract][Full Text] [Related]
2. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Tatsumoto T; Kuroki-Migita M; Mitsugi K; Nakamura M; Niho Y
Cancer Res; 1992 Dec; 52(23):6501-6. PubMed ID: 1423296
[TBL] [Abstract][Full Text] [Related]
3. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line.
Masumoto N; Nakano S; Esaki T; Tatsumoto T; Fujishima H; Baba E; Nakamura M; Niho Y
Anticancer Res; 1995; 15(2):405-9. PubMed ID: 7763013
[TBL] [Abstract][Full Text] [Related]
4. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Ikuno N; Soda H; Watanabe M; Oka M
J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
[TBL] [Abstract][Full Text] [Related]
6. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells.
Minagawa Y; Kigawa J; Ishihara H; Itamochi H; Terakawa N
Jpn J Cancer Res; 1994 Sep; 85(9):966-71. PubMed ID: 7961127
[TBL] [Abstract][Full Text] [Related]
7. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Masumoto N; Fujishima H; Niho Y
Int J Cancer; 1996 Feb; 65(4):479-84. PubMed ID: 8621231
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
[TBL] [Abstract][Full Text] [Related]
9. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
Fujishima H; Nakano S; Masumoto N; Esaki T; Tatsumoto T; Kondo T; Niho Y
Oncol Res; 1997; 9(4):167-72. PubMed ID: 9268987
[TBL] [Abstract][Full Text] [Related]
10. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
Ma J; Maliepaard M; Nooter K; Boersma AW; Verweij J; Stoter G; Schellens JH
Cancer Chemother Pharmacol; 1998; 41(4):307-16. PubMed ID: 9488600
[TBL] [Abstract][Full Text] [Related]
11. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair.
Bungo M; Fujiwara Y; Kasahara K; Nakagawa K; Ohe Y; Sasaki Y; Irino S; Saijo N
Cancer Res; 1990 May; 50(9):2549-53. PubMed ID: 2158392
[TBL] [Abstract][Full Text] [Related]
12. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
Minagawa Y; Kigawa J; Itamochi H; Terakawa N
Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
[TBL] [Abstract][Full Text] [Related]
13. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
[TBL] [Abstract][Full Text] [Related]
14. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
Kanzawa F; Koizumi F; Koh Y; Nakamura T; Tatsumi Y; Fukumoto H; Saijo N; Yoshioka T; Nishio K
Clin Cancer Res; 2001 Jan; 7(1):202-9. PubMed ID: 11205910
[TBL] [Abstract][Full Text] [Related]
15. v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells.
Masumoto N; Nakano S; Fujishima H; Kohno K; Niho Y
Int J Cancer; 1999 Mar; 80(5):731-7. PubMed ID: 10048975
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin.
Goldwasser F; Valenti M; Torres R; Kohn KW; Pommier Y
Clin Cancer Res; 1996 Apr; 2(4):687-93. PubMed ID: 9816219
[TBL] [Abstract][Full Text] [Related]
17. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
Kawato Y; Aonuma M; Hirota Y; Kuga H; Sato K
Cancer Res; 1991 Aug; 51(16):4187-91. PubMed ID: 1651156
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
Ali-Osman F; Berger MS; Rajagopal S; Spence A; Livingston RB
Cancer Res; 1993 Dec; 53(23):5663-8. PubMed ID: 8242621
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
20. In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer.
Tsunoda T; Tanimura H; Hotta T; Tani M; Iwahashi M; Ishimoto K; Tanaka H; Matsuda K; Yamaue H
J Surg Oncol; 2000 Jan; 73(1):6-11. PubMed ID: 10649271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
